You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Tuesday, March 21, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

      Clinical Advances in

      Key Psychiatric Conditions: A Focus on Schizophrenia

      Read Overview

      Supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.

      Overview

      Schizophrenia is a group of chronic, neurodevelopmental disorders marked by progressive brain changes, gray- and white-matter loss, and increases in ventricular volume. Symptoms include hallucinations and delusions (positive symptoms); flat affect, disorganized thought, and low motivation (negative symptoms); and impairments in executive function, attention, and working memory (cognitive symptoms). The currently available antipsychotics mostly treat the positive symptoms of schizophrenia and have a least 1 adverse effect as a potential liability. Encouraging data suggest potential efficacy from a variety of new agents for the treatment of total symptoms and/or specific symptom domains of schizophrenia. These resources will provide the tools that clinicians need to appropriately diagnose and manage patients with this psychiatric condition and understand the mechanisms of action of emerging pharmaceutical approaches.

      CME Activities

      Advances in Schizophrenia

      Examine How New Agents Are Trying to Improve All the Symptoms of Schizophrenia

      Resources

      Downloadable Slide Kit
      Related Links
      Clinical References

      Steering Committee

      Christoph Correll, MD
      Christoph U. Correll, MD

      Steering Committee Member Chair

      Professor of Psychiatry and Molecular Medicine
      Zucker School of Medicine
      Hofstra University/Northwell Health
      New York, New York

      Bio Video
      Kelly L. Deanna, PharmD, BCPP
      Deanna L. Kelly, PharmD, BCPP

      MPower Professor of Psychiatry
      University of Maryland Strategic Partnership: MPowering the State
      University of Maryland School of Medicine
      Catonsville, Maryland

      Bio Video
      Danielle Hairston, MD
      Danielle Hairston, MD

      Assistant Professor of Psychiatry
      Howard University College of Medicine/Hospital,
      Washington, DC

      Bio Video
      Jonathan M. Meyer, MD
      Jonathan M. Meyer, MD

      Voluntary Clinical Professor
      Department of Psychiatry
      University of California, San Diego

      Bio Video
      Diana O. Perkins, MD, MPH
      Diana O. Perkins, MD, MPH

      Professor, Department of Psychiatry,
      University of North Carolina at Chapel Hill

      Bio Video
      Andrew J. Cutler, MD
      Andrew J. Cutler, MD

      Clinical Associate Professor of Psychiatry
      SUNY Upstate Medical University
      Syracuse, New York

      Bio Video

      Disclosures

      Steering Committee

      Christoph Correll, MD
      Christoph U. Correll, MD

      Steering Committee Chair

      Christoph U. Correll, MD, has disclosed the following relevant financial relationships:

      Consultant or advisor for: AbbVie; Acadia; Alkermes; Allergan; Angelini; Aristo; Boehringer Ingelheim; Cardio Diagnostics; Cerevel; CNX; Compass Pathways; Damitsa; Gedeon Richter; Hikma; Holmusk; Intracellular; Janssen; Johnson & Johnson; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mindpax; Mitsubishi Tanabe; Mylan; Neurocrine; Noven; Otsuka; Pharmabrain; Recordati; Relmada; Reviva; Rovi; Seqirus; Servier; SK Life Science; Sunovion; Sun; Supernus; Takeda; Teva; Viatris

      Speaker or member of speakers bureau for: AbbVie; Angelini; Aristo; Damitsa; Gedeon Richter; Hikma; Intracellular; Janssen; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe; Mylan; Otsuka; Recordati; Seqirus; Sunovion; Takeda; Viatris

      Research funding from: Janssen; Takeda

      Contracted researcher for: Janssen

      Stock options from: Cardio Diagnostics; LB Pharma; Mindpax

      Kelly L. Deanna, PharmD, BCPP
      Deanna L. Kelly, PharmD, BCPP

      Deanna L. Kelly, PharmD, BCPP, MD, has disclosed the following relevant financial relationships:

      Consultant or advisor for: Alkermes; Janssen; Sunovion

      Research funding from: Saladax

      Danielle Hairston, MD
      Danielle Hairston, MD

      Danielle Hairston, MD, has no relevant financial relationships.

      Jonathan M. Meyer, MD
      Jonathan M. Meyer, MD

      Jonathan M. Meyer, MD, has the following relevant financial relationships:

      Consultant or advisor for: Acadia; Alkermes; Intra-Cellular; Karuna; Neurocrine; Otsuka; Sunovion; Teva

      Speaker or member of speakers bureau for: Alkermes; Intra-Cellular; Noven; Sunovion; Teva

      Diana O. Perkins, MD, MPH
      Diana O. Perkins, MD, MPH

      Diana O. Perkins, MD, MPH, has disclosed the following relevant financial relationships:

      Consultant or advisor for: Alkermes; Karuna

      Contracted researcher for: Boehringer Ingelheim

      Andrew J. Cutler, MD
      Andrew J. Cutler, MD

      Andrew J. Cutler, MD, has the following relevant financial relationships:

      Consultant or advisor for: AbbVie; Acadia; Alfasigma; Alkermes; Allergan; BioXcel; Corium; Intra-Cellular; Ironshore; Janssen; Lundbeck; Neumora; Neurocrine; Noven; Otsuka; Pear; Relmada; Sage; Sunovion; Supernus; Takeda; Teva

      Speaker or member of speakers bureau for: AbbVie; Acadia; Alfasigma; Alkermes; Allergan; BioXcel; Corium; IntraCellular; Ironshore; Janssen; Lundbeck; Neurocrine; Noven; Otsuka; Sunovion; Supernus; Takeda; Teva

      Discussion

      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.